Ani Pharmaceuticals (ANIP)
NASDAQ:ANIP
Want to see ANIP full AI Analyst Report?
ANIP Stock Chart & Stats
$80.92
<$0.01(0.02%)
At close: 4:00 PM EST
$80.92
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$61.18 - $99.50
Previous CloseN/A
Volume18.69K
Average Volume (3M)375.83K
Market Cap
$1.85B
Enterprise Value$1.80B
Total Cash (Recent Filing)$311.18M
Total Debt (Recent Filing)$327.76M
Price to Earnings (P/E)18.9
Beta0.51
Next Earnings
Aug 12, 2026EPS Estimate
2.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.11
Shares Outstanding22,734,617
10 Day Avg. Volume379,487
30 Day Avg. Volume375,829
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.93
Price to Sales (P/S)1.79
P/FCF Ratio9.24
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.96
Enterprise Value/Ebitda7.60
Forecast
1Y Price Target
$115.20Price Target Upside42.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)9.37
Revenue Forecast (FY)$1.12B
Bulls Say, Bears Say
Bulls Say
Revenue Scale-upANI has delivered durable top-line expansion over multiple years, demonstrating successful commercialization and portfolio scale. Sustained revenue growth improves operating leverage, funds reinvestment in launches and rare-disease commercialization, and reduces single-product dependency over the medium term.
Strong Cash GenerationConsistently positive and growing free cash flow supports organic investment, M&A optionality, debt reduction and shareholder returns. Robust cash generation provides a durable financial cushion against execution swings and underpins strategic expansion in Rare Disease and generics over the next 2–6 months.
Clear Strategic Momentum & GuidanceManagement upgraded full-year guidance and emphasizes Rare Disease scale (Cortrophin-led), reflecting improving underlying demand and validated commercial execution. A clear growth roadmap and confirmed guidance support planning, resource allocation and sustainable revenue visibility into 2026–2027.
Bears Say
Gross-margin PressureMargin erosion from a higher mix of royalty-bearing products, partnered generics and lost prior-year revenues points to structural margin mix risk. Persistently lower gross margins would compress operating profitability and limit the leverage from revenue growth absent offsetting cost or price improvements.
Capital-structure VolatilityHistoric swings in leverage indicate earnings and cashflow sensitivity to operational hiccups. While current leverage is moderate, the prior spike shows limited structural resilience in downturns, which can constrain strategic flexibility (M&A, capex, buybacks) if performance softens again.
Market Access & Timing RisksPersistent payer and access headwinds for ILUVIEN and recurrent insurance reverifications create durable revenue visibility issues and higher commercial execution costs. These structural access constraints can slow uptake of growing products and increase sensitivity to timing of milestones and one‑time payments.
ANI Pharmaceuticals News
ANIP FAQ
What was Ani Pharmaceuticals’s price range in the past 12 months?
Ani Pharmaceuticals lowest stock price was $61.17 and its highest was $99.50 in the past 12 months.
What is Ani Pharmaceuticals’s market cap?
Ani Pharmaceuticals’s market cap is $1.85B.
When is Ani Pharmaceuticals’s upcoming earnings report date?
Ani Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 63 days.
How were Ani Pharmaceuticals’s earnings last quarter?
Ani Pharmaceuticals released its earnings results on May 08, 2026. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.299 by $0.751.
Is Ani Pharmaceuticals overvalued?
According to Wall Street analysts Ani Pharmaceuticals’s price is currently Undervalued.
Does Ani Pharmaceuticals pay dividends?
Ani Pharmaceuticals does not currently pay dividends.
What is Ani Pharmaceuticals’s EPS estimate?
Ani Pharmaceuticals’s EPS estimate is 2.02.
How many shares outstanding does Ani Pharmaceuticals have?
Ani Pharmaceuticals has 22,734,617 shares outstanding.
What happened to Ani Pharmaceuticals’s price movement after its last earnings report?
Ani Pharmaceuticals reported an EPS of $2.05 in its last earnings report, beating expectations of $1.299. Following the earnings report the stock price went down -2.443%.
Which hedge fund is a major shareholder of Ani Pharmaceuticals?
Currently, no hedge funds are holding shares in ANIP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ANI Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.20 (42.36% Upside)
$115.20 (42.36% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 769.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.32%
12-Months-Change
Fundamentals
Return on Equity
17.32%
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Ani Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANIP Company Deck
ANIP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and material financial progress: consolidated Q1 revenue growth (20% YoY), Cortrophin Gel growth (42% YoY), adjusted EBITDA and EPS expansion, raised 2026 guidance, near-term cash from an IP out-license, an active product launch cadence in Generics, and a sizeable commercial expansion into acute gouty arthritis flares. Offsetting items include margin pressure from a higher mix of royalty-bearing products and new launches, temporary insurance reverification and access headwinds that impacted Q1 timing, increased SG&A from sales expansion, and some reliance on timing of upfront/milestone payments. Overall, positives (revenue/EBITDA growth, guidance raise, strategic investments and M&A optionality, cash position, repurchase program) materially outweigh the lowlights (margin compression, access and timing issues), supporting a constructive outlook for 2026 and into 2027.View all ANIP earnings summariesANIP Stock 12 Month Forecast
Average Price Target
$115.20
▲(42.36% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―
Ownership Overview
7.89% Insiders
19.56% Mutual Funds
38.53% Other Institutional Investors
11.27% Public Companies and
Individual Investors